After years of debate, the federal government, for the first time, will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D and Part B. This comes under the Inflation Reduction Act.

The first ten Part D drugs selected for Medicare price negotiation include treatments for diabetes, blood clots, heart failure, psoriasis, rheumatoid arthritis, Crohn’s disease, and blood cancers. The Medicare negotiated drug prices for these drugs won’t take effect until January 1, 2026.

Below is a list of drugs being negotiated:

Get more information, including several informational charts, here.